Signposting evidence-based information on the treatment of constipation in pregnancy

Condition Management

Constipation is common in pregnancy affecting approximately 40% of women. It is thought to be caused by progesterone-induced intestinal smooth muscle relaxation.

It is important to complete an individual risk assessment for your patient and to apply the principles of prescribing during pregnancy when looking at the available information and making treatment decisions. Check to see if a risk assessment has already been completed.


NICE CKS Constipation refers to UKTIS Treatment of constipation in pregnancy for advice on medicines to treat constipation.

You should check if there is local guidance for you to use in your area.

Stepwise recommendations

The CKS recommends a stepwise approach starting with non-pharmacological measures if appropriate or possible, through the range of pharmacological options:

Non-pharmacological management

  • Exercise, dietary measures and increased fluid intake.

Pharmacological management

If lifestyle measures are ineffective, or symptoms do not respond adequately, offer short-term treatment with oral laxatives.

Adjust the dose, choice, and combination, depending on symptoms, the desired speed of symptom relief, the response to treatment, and the woman’s personal preference.

First line

Bulk-forming laxatives e.g. ispaghula husk, sterculia or wheat bran.

Second line

Osmotic laxatives lactulose and macrogol – the manufacturers state that use in pregnancy may be considered if necessary.

Other options

If stools are soft but difficult to pass, or there is a sensation of incomplete emptying, consider a short course of a stimulant such as senna.

If the response to treatment is still inadequate, consider a glycerol suppository.

Pregnancy outcome information

The UK Teratology Information Service (UKTIS) provides an overview of the treatment of constipation in pregnancy which provides information on the individual treatments.

Patient information

Each of the UKTIS summaries has corresponding Best Use of Medicine in Pregnancy (BUMPS) patient information.

NHS Medicines A-Z provides a summary statement on the use in pregnancy of specific medicines include isphagula husk, lactulose, macrogol and senna.

Support for prescribing decisions in people on interacting medicines, those with swallowing difficulties, renal impairment, or who are pregnant or breastfeeding
SPS protocol templates for the supply and administration of omeprazole for pre planned caesarean section by registered midwives.
SPS PGD template for administering subcutaneous terbutaline sulfate for the reduction of contraction frequency in individuals in labour.
SPS PGD template for the intrapartum administration of benzylpenicillin for prevention of early-onset Group B Streptococcus (GBS) infection in neonates.
Opioid analgesics may be used at any stage of pregnancy at the lowest effective dose for the short-term relief of pain when other analgesics are not effective.
Intramuscular hydroxocobalamin is the preferred treatment choice for management of clinically relevant vitamin B12 deficiency, including during pregnancy.
SPS PGD template for the supply of folic acid 5mg tablets to reduce risk of neural tube defect or compensate for increased folate demand during pregnancy.
SPS PGD template for the supply of aspirin tablets to individuals at risk of pre-eclampsia during pregnancy.
Signposting evidence-based information on the treatment of pain in pregnancy
Signposting evidence-based information on the treatment of urinary tract infection in pregnancy

Print this page